Efficacy and safety of omalizumab in patients with chronic idiopathic urticaria who remain symptomatic despite concomitant H1 antihistamine therapy: results of a phase 2 trial

被引：0
|
作者：
Saini, S.
Rosen, K. [1 ]
Hsieh, H. [1 ]
Wong, D. [1 ]
Conner, E.
Doyle, R. [1 ]
Kaplan, A. [2 ]
Spector, S. [3 ]
Maurer, M. [4 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Med Univ S Carolina, Charleston, SC USA
[3] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[4] Charite Univ Med Berlin, Berlin, Germany
来源：
ALLERGY | 2011年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
67
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] Angioedema and Angioedema Management From Asteria I and Asteria II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
    Zazzali, James
    Rosen, Karin
    Bradley, Mary S.
    Raimundo, Karina
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB117 - AB117
  • [2] Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study
    Saini, Sarbjit S.
    Bindslev-Jensen, Carsten
    Maurer, Marcus
    Grob, Jean-Jacques
    Baskan, Emel Bulbul
    Bradley, Mary S.
    Canvin, Janice
    Rahmaoui, Abdelkader
    Georgiou, Panayiotis
    Alpan, Oral
    Spector, Sheldon
    Rosen, Karin
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (01) : 67 - 75
  • [3] Improvements In Health-Related Quality Of Life From Asteria I & II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
    Raimundo, Karina
    Zazzali, James
    Trzaskoma, Benjamin
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB118 - AB118
  • [4] Angioedema and angioedema management from ASTERIA II: a phase III, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 antihistamine treatment
    Zazzali, J. L.
    Rosen, K. E.
    Hsieh, H-J
    ALLERGY, 2013, 68 : 43 - 43
  • [5] Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study (vol 135, pg 67, 2015)
    Saini, Sarbjit S.
    Bindslev-Jensen, Carsten
    Maurer, Marcus
    Grob, Jean-Jacques
    Baskan, Emel Buelbuel
    Bradley, Mary S.
    Canvin, Janice
    Rahmaoui, Abdelkader
    Georgiou, Panayiotis
    Alpan, Oral
    Spector, Sheldon
    Rosen, Karin
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (03) : 925 - 925
  • [6] Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
    Kaplan, Allen
    Ledford, Dennis
    Ashby, Mark
    Canvin, Janice
    Zazzali, James L.
    Conner, Edward
    Veith, Joachim
    Kamath, Nikhil
    Staubach, Petra
    Jakob, Thilo
    Stirling, Robert G.
    Kuna, Piotr
    Berger, William
    Maurer, Marcus
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (01) : 101 - 109
  • [7] EFFICACY AND SAFETY OF OMALIZUMAB IN H1-ANTIHISTAMINE-REFRACTORY CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA: RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Saini, S. S.
    Bindslev-Jensen, C.
    Maurer, M.
    Grob, J. J.
    Baskan, E. Bulbul
    Bradley, M. S.
    Georgiou, P.
    Alpan, O.
    Spector, S.
    Rosen, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A18 - A18
  • [8] Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
    Martin Metz
    Gordon Sussman
    Rémi Gagnon
    Petra Staubach
    Tonny Tanus
    William H. Yang
    Jeremy J. Lim
    Holly J. Clarke
    Joshua Galanter
    Leslie W. Chinn
    Tom Chu
    Anastasia Teterina
    Tracy Burgess
    D. James Haddon
    Timothy T. Lu
    Marcus Maurer
    Nature Medicine, 2021, 27 : 1961 - 1969
  • [9] Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
    Metz, Martin
    Sussman, Gordon
    Gagnon, Remi
    Staubach, Petra
    Tanus, Tonny
    Yang, William H.
    Lim, Jeremy J.
    Clarke, Holly J.
    Galanter, Joshua
    Chinn, Leslie W.
    Chu, Tom
    Teterina, Anastasia
    Burgess, Tracy
    Haddon, D. James
    Lu, Timothy T.
    Maurer, Marcus
    NATURE MEDICINE, 2021, 27 (11) : 1961 - +
  • [10] Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase b Study
    Lu, Qianjin
    Yang, Bin
    Liu, Lunfei
    Li, Linfeng
    Liu, Weijun
    Yao, Xu
    Man, Xiaoyong
    Chen, Aijun
    Shi, Yuling
    Ding, Yangfeng
    Sun, Qing
    Tao, Juan
    Liang, Chris
    Liu, Yong
    Liu, Donghua
    Sun, Peiyu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB372 - AB372
12345